Shots:

• The US FDA has granted BTD to the company’s non-invasive pan-amyloid PET imaging agent, 124I-evuzamitide (AT-01), intended for the diagnosis of cardiac amyloidosis. It has also been designated with the US FDA & EC’s ODD for ATTR & AL amyloidosis
• The designation was based on the results from Attralus-sponsored & investigator-initiated trials assessing 124I-evuzamitide among cardiac amyloidosis patients. Its P-III trial is expected during H1’25
• 124I-evuzamitide, labeled with iodine-124, is an amyloid-specific imaging agent intended to detect all kinds of systemic amyloidosis. It can identify amyloid deposits such as ATTR & AL, in organs like the heart, kidney, liver, and spleen as demonstrated in clinical evaluations